Table of Contents Table of Contents
Previous Page  63 / 104 Next Page
Information
Show Menu
Previous Page 63 / 104 Next Page
Page Background

61

NCCN Guidelines for Patients

®

:

Ovarian Cancer, Version 1.2017

5

Treatment guide

Follow-up after initial treatment

Guide 12. Recurrence treatment

Preferred options

If cancer is platinum-sensitive:

If cancer is platinum-resistant:

Targeted therapy

(single agent)

• Carboplatin

• Docetaxel

• Bevacizumab

• Carboplatin/docetaxel

• Etoposide (oral)

• Olaparib

• Carboplatin/gemcitabine

• Gemcitabine

• Rucaparib (if cancer is

platinum-resistant)

• Carboplatin/gemcitabine/bevacizumab

• Liposomal doxorubicin

• Carboplatin/liposomal doxorubicin

• Liposomal doxorubicin/

bevacizumab

• Carboplatin/paclitaxel, albumin bound

(for patients with taxane hypersensitivity)

• Paclitaxel (weekly)

± pazopanib

• Carboplatin/paclitaxel

• Paclitaxel (weekly)/bevacizumab

• Carboplatin/paclitaxel (weekly)

• Topotecan

• Cisplatin

• Topotecan/bevacizumab

• Cisplatin/gemcitabine

Other options

• Altretamine

• Melphalan

• Aromatase inhibitors

• Oxaliplatin

• Capecitabine

• Palliative radiation therapy

• Cyclophosphamide

• Paclitaxel

• Carboplatin/paclitaxel/bevacizumab

(if cancer is plantinum-sensitive)

• Paclitaxel, albumin-bound

• Doxorubicin

• Pazopanib

• Ifosfamide

• Pemetrexed

• Irinotecan

• Rucaparib (if cancer is plantinum-sensitive)

• Leuprolide acetate

• Tamoxifen

• Megestrol acetate

• Vinorelbine